Related references
Note: Only part of the references are listed.Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT
Takayuki Inoue et al.
JCI INSIGHT (2021)
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
Marisa P. McGinley et al.
LANCET (2021)
Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis
Emi Yokoyama et al.
BONE MARROW TRANSPLANTATION (2020)
Treatment and unmet needs in steroid-refractory acute graft-versus-host disease
Florent Malard et al.
LEUKEMIA (2020)
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD
Bruce R. Blazar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
Maxi Kaufmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation
Karina Jordan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome
Haesook T. Kim et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Evidence for the involvement of sphingosine-1-phosphate in the homing and engraftment of hematopoietic stem cells to bone marrow
Mateusz Adamiak et al.
ONCOTARGET (2015)
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension
Jun-ichi Kira et al.
BMC NEUROLOGY (2014)
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice
T. Ruutu et al.
BONE MARROW TRANSPLANTATION (2014)
Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis
Melanie D. Ward et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial
Andrea Vaclavkova et al.
LANCET (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis
T. Saida et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade
Enric Carreras et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice
Jinghai Song et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)
Patricia A. Taylor et al.
BLOOD (2007)
FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease
Daigo Hashimoto et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Causes and risk factors for liver injury following bone marrow transplantation
O Özdogan et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2003)
Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720
YM Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia
N Schmitz et al.
BLOOD (2002)
Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study
BK Kim et al.
BONE MARROW TRANSPLANTATION (2000)
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory
DD Pinschewer et al.
JOURNAL OF IMMUNOLOGY (2000)